264 related articles for article (PubMed ID: 27406316)
1. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Ferrari A; Vincent-Salomon A; Pivot X; Sertier AS; Thomas E; Tonon L; Boyault S; Mulugeta E; Treilleux I; MacGrogan G; Arnould L; Kielbassa J; Le Texier V; Blanché H; Deleuze JF; Jacquemier J; Mathieu MC; Penault-Llorca F; Bibeau F; Mariani O; Mannina C; Pierga JY; Trédan O; Bachelot T; Bonnefoi H; Romieu G; Fumoleau P; Delaloge S; Rios M; Ferrero JM; Tarpin C; Bouteille C; Calvo F; Gut IG; Gut M; Martin S; Nik-Zainal S; Stratton MR; Pauporté I; Saintigny P; Birnbaum D; Viari A; Thomas G
Nat Commun; 2016 Jul; 7():12222. PubMed ID: 27406316
[TBL] [Abstract][Full Text] [Related]
2. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
[TBL] [Abstract][Full Text] [Related]
4. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Lesurf R; Griffith OL; Griffith M; Hundal J; Trani L; Watson MA; Aft R; Ellis MJ; Ota D; Suman VJ; Meric-Bernstam F; Leitch AM; Boughey JC; Unzeitig G; Buzdar AU; Hunt KK; Mardis ER
Ann Oncol; 2017 May; 28(5):1070-1077. PubMed ID: 28453704
[TBL] [Abstract][Full Text] [Related]
5. Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypes.
Pan JW; Ragu M; Chan WQ; Hasan SN; Islam T; Teoh LY; Jamaris S; See MH; Yip CH; Rajadurai P; Looi LM; Taib NAM; Rueda OM; Caldas C; Chin SF; Lim J; Teo SH
Breast Cancer Res; 2024 Apr; 26(1):67. PubMed ID: 38649964
[TBL] [Abstract][Full Text] [Related]
6. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
7. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
10. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Zhao S; Liu XY; Jin X; Ma D; Xiao Y; Shao ZM; Jiang YZ
Theranostics; 2019; 9(17):4935-4945. PubMed ID: 31410192
[No Abstract] [Full Text] [Related]
11. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC
Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.
Umemura S; Shirane M; Takekoshi S; Kusakabe T; Itoh J; Egashira N; Tokuda Y; Mori K; Osamura YR
Br J Cancer; 2009 Mar; 100(5):764-71. PubMed ID: 19259095
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
14. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.
Groenendijk FH; Zwart W; Floore A; Akbari S; Bernards R
Breast Cancer Res Treat; 2013 Aug; 140(3):475-84. PubMed ID: 23912957
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
18. Triple negative tumours: a critical review.
Reis-Filho JS; Tutt AN
Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
20. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
Cheng Q; Chang JT; Geradts J; Neckers LM; Haystead T; Spector NL; Lyerly HK
Breast Cancer Res; 2012 Apr; 14(2):R62. PubMed ID: 22510516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
